Guardant Health (GH) announced the National Cancer Institute, or NCI, has selected the company’s Shield multi-cancer detection test for use in its Vanguard study, which will address the feasibility of using MCD tests in future clinical trials related to cancer screening. MCD tests are blood tests that can screen for several types of cancers simultaneously.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health enters partnership with MiBA
- Guardant Health and COTA partner in advanced oncology R&D
- Guardant Health announces collaboration with Boehringer Ingelheim
- Guardant says jury unanimously found in favor of company in Natera suit
- Natera ‘disagrees’ with jury’s decision in Guardant Health litigation